Neurocrine Biosciences | NBIX - Ordinary Share Capital

Stock Price
158.42
Daily Change
-0.63 -0.40%
Monthly
23.37%
Yearly
30.90%
Q2 Forecast
149.10

Neurocrine Biosciences reported $100.6M in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Acadia Pharmaceuticals USD 169.18M 470K Dec/2025
Agios Pharmaceuticals USD 59.34M 892K Mar/2026
ALKERMES USD 166.46M 855K Mar/2026
Alnylam Pharmaceuticals USD 133.44M 1.07M Mar/2026
Amgen USD 540M 1000K Mar/2026
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 193.27M 969K Mar/2026
Cytokinetics USD 124.43M 2.17M Mar/2026
Enanta Pharmaceuticals USD 212K 1000 Dec/2023
Exelixis USD 253.7M 8.78M Mar/2026
Gilead Sciences USD 1.24B 1000K Mar/2026
Halozyme Therapeutics USD 118.52M 741K Mar/2026
Incyte USD 199.95M 1.49M Mar/2026
Ionis Pharmaceuticals USD 165.9M 3.93M Mar/2026
Nektar Therapeutics USD 20.38M 20.36M Dec/2025
Neurocrine Biosciences USD 100.6M 500K Mar/2026
Pfizer USD 5.7B 13M Mar/2026
Prothena USD 53.83M 3K Dec/2025
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Repligen USD 56.4M 74K Mar/2026
Rigel Pharmaceuticals USD 17K 158K Jun/2024
Sarepta Therapeutics USD 105.57M 607K Mar/2026
Teva Pharmaceutical Industries USD 1.16B 16.72M Mar/2026
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
Vertex Pharmaceuticals USD 254.2M 200K Mar/2026
Xoma USD 87K 1000 Jun/2024